New Results from Examining Anti-Cancer Effects of Immune-12 on GBM Cells

Andrew Satterlee from UNC presented Immune 12 pre-clinical research at the 7th Quadrennial Meeting of the World Federation of Neuro-Oncology Societies, held in conjunction with the 30th Society for Neuro-Oncology (SNO) Annual Meeting & Education Day in Honolulu, Hawaii. Nov. 19-23, 2025.

Examining Anti-Cancer Effects of Immune-12 on GBM Cells

Glioblastoma (GBM) remains one of the most lethal and treatment-resistant cancers, underscoring the urgent need for novel therapeutic strategies. Marine-derived nutraceuticals offer a promising avenue due to their unique and myriad bioactive compounds. Immune-12 is an orally available marine organism-derived product that has shown preliminary evidence of anticancer activity in the published literature. Now, our team is conducting a comprehensive investigation …